Navigation Links
PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million
Date:12/1/2009

INCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with $69 million for the fourth quarter of 2008. Included in fourth quarter 2008 results was the first of two installment payments of $12.5 million from Alexion. Also included in fourth quarter 2008 results was a one-time $1.8 million payment from Genentech for the exercise of options to four additional antigens and extension of the option period for two antigens under its license agreement with PDL.

Royalty revenues are based on third quarter product sales by PDL's licensees and include $3.2 million for Synagis®, which is marketed by MedImmune. When compared with 2008, underlying product sales of Avastin® and Lucentis®, for which the average royalty rate paid in the fourth quarter was 1%, increased by greater than 25% and sales of Tysabri®, for which the underlying royalty rate is 3%, increased by 23%. Underlying product sales of Synagis®, for which the average royalty rate was 3%, decreased by more than 25%. Royalties from sales of Herceptin® decreased 8% despite an 8% increase in underlying Herceptin sales because of a change in the sales mix of ex-US manufactured Herceptin for which the Company receives a flat 3% royalty rate and US manufactured Herceptin for which the fourth quarter effective rate received from Genentech/Roche for US manufactured products was 1%.

The above guidance is preliminary and actual published results may differ from such guidance. PDL plans to release its financial results for the fourth quarter 2009 in late February 2010 and will hold a conference call to discuss financial results and provide an update on company activities. Additional infor
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Scientists, including University of Oregon chemist Geraldine ... scaffolds of self-assembling, synthetic proteins called peptoid nanosheets ... The accomplishment -- detailed this week in a ... Proceedings of the National Academy of Sciences ... design of the two-dimensional peptoid nanosheets that can ...
(Date:9/2/2014)... Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... approach for protecting personal data in Clinical Study ... and others. The document describes an approach to ... CSRs and other related clinical trial documents, and ... goal of the TransCelerate CSR Redaction approach is ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ... M.D., President and Chief Executive Officer, will present at the ... in New York on Tuesday, Sept. ... live and archived webcast of the presentation will be accessible ... "News & Events" section. About Oncothyreon ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... have created the first "active matrix" display using a ... toward realizing applications such as e-paper, flexible color monitors ... are made of "nanowires," tiny cylindrical structures that are ... The researchers used nanowires as small as 20 nanometers ...
... March 31 Chem Rx,Corporation (OTC Bulletin Board: ... services, announced today that it will hold a,conference ... 2008 outlook,on April 1, 2008 at 8:30 a.m. ... Steven C. Silva, President and Chief Operating,Officer, will ...
... ALTO, Calif., March 31 Varian, Inc.,(NasdaqGS: ... VF-5ht UltiMetal(TM),column for high temperature gas chromatography ... operating conditions. These highly durable columns,allow chemists ... temperatures, up,to 450 degrees Celsius. Based on ...
Cached Biology Technology:Engineers make first 'active matrix' display using nanowires 2Engineers make first 'active matrix' display using nanowires 3Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results 2New Capillary Column From Varian, Inc. Offers Durability and Performance for High Temperature GC and GC/MS 2
(Date:9/2/2014)... everyone has a tipping point. We all want to be ... is great enough. Now, scientists have confirmed the area of ... The result was published online this week in ... even if lying is beneficial," said Lusha Zhu, the study,s ... Tech Carilion Research Institute , where she works with Brooks ...
(Date:9/2/2014)... Sam Kean stops by Reactions this week to debunk ... that, despite what "Shark Week" may lead you to ... http://youtu.be/KhFygIoW_MA . , Kean,s book, "The Disappearing Spoon: ... History of the World from the Periodic Table of ... 10-episode video series produced for the newly launched American ...
(Date:9/2/2014)... for eating anything, including each other, camel crickets are ... Carolina State University finds that non-native camel cricket species ... , "The good news is that camel crickets don,t ... says Dr. Mary Jane Epps, a postdoctoral researcher at ... the research. , The research stems from a chance ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Researchers find Asian camel crickets now common in US homes 2
... State University and the University of Oxford are the ... how migrating birds use light and Earth,s weak magnetic ... 30, 2008, online issue of Nature that the photochemical ... weak magnetic fields similar to Earth,s when exposed to ...
... researchers have succeeded in wiping out established biofilms ... the bacteria,s own regulatory systems. Although the discovery ... offer insight into a dispersal mechanism for staph ... Biofilms are communities of bacteria that grow on ...
... the UN Conference on Climate Change (COP15) to be held ... to organise this conference as part of the run-up to ... try and capture some of the enormous research energy currently ... change. Thus, the focus of the conference is on providing ...
Cached Biology News:A model photochemical compass for bird navigation 2A model photochemical compass for bird navigation 3Turning on cell-cell communication wipes out staph biofilms 2Turning on cell-cell communication wipes out staph biofilms 3
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: